# TRAVERE THERAPEUTICS, INC. (TVTX) · Edgar & Edgarette company card

> Travere Therapeutics (TVTX) grew revenue 110% in FY2025 to $491 million, operating margin -12.8% against a -3.8% median for pharmaceutical preparations, equity 19.0% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1438533 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/TVTX) · [JSON](https://www.pops4.com/boards/company/TVTX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $491M |
| Revenue growth, 1 year | 110.5% |
| Revenue growth per year | 38.9% |
| Operating margin | -12.8% (prior year -138.9%) |
| Net margin | -5.2% |
| Operating cash flow | $38M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $93M |
| Long-term debt | — |
| Total assets | $605M |
| Total equity | $115M |
| Equity ÷ assets | 19.0% |
| Return on equity | -22.2% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -5.38 (distress zone)
- Piotroski F: 7 of 9 (solid)
- Beneish M: -1.51 (above the −1.78 line)
- Health Harbor boat: Weathered boat · two warning signs · operating loss: a margin of -12.8% in FY2025; revenue is hard to predict: its 80% range is ±44%
- Cash Compass: Cash cow later · growing fast, and already turning revenue into cash

## Edgarette's reading

Exposure: revenue $490.7M (FY2025). Experience: revenue up 110.5% on the year, up 38.9% a year over 4 years; operating margin -12.8%, up from -138.9%. Soundness: equity 19.0% of assets, return on equity -22.2%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $568.2M and $1.5B next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $448.2M to $1.9B. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -12.8% against a -3.8% median; growth 110.5% against 13.7%.

Range logged 2026-09-24, receipt 06d68c593b4c5d9d, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 4, latest 2026-09-21 ([filing](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000068/0001438533-26-000068-index.htm))

## Recent filings

- 10-Q · filed 2026-11-02 · [filing](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000077/0001438533-26-000077-index.htm)
- 8-K · filed 2026-11-02 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000074/0001438533-26-000074-index.htm)
- 8-K · filed 2026-09-21 · 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000068/0001438533-26-000068-index.htm)
- 10-Q · filed 2026-08-04 · [filing](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000063/0001438533-26-000063-index.htm)
- 8-K · filed 2026-08-04 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000062/0001438533-26-000062-index.htm)
- 8-K · filed 2026-07-09 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000054/0001438533-26-000054-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001438533.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1438533

## Cite

POPS4, Edgar & Edgarette: TRAVERE THERAPEUTICS, INC. (TVTX) company card, from the company's own SEC filings, accessed 2026-11-06, https://www.pops4.com/boards/company/TVTX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.